Pilot Study of the Role of 11-dh-TXB2 in Prostate Cancer Screening and Diagnosis
OBJECTIVES:
- To identify a potential novel marker of prostate cancer in the blood and urine,
11-dh-TXB2, to be used as a screening tool for prostate cancer as well as in detection
of early relapse in patients previously treated for early-stage prostate cancer.
OUTLINE: Blood and urine samples are collected and analyzed for plasma and urinary
11-dh-TXB2 levels by HPLC and tandem-mass spectrometry.
Observational
Observational Model: Case Control, Time Perspective: Prospective
Identification of 11-dh-TXB2 in the blood and urine
2 to 4 months
No
Elisabeth I. Heath, MD
Principal Investigator
Barbara Ann Karmanos Cancer Institute
United States: Federal Government
CDR0000654093
NCT00984919
November 2009
February 2011
Name | Location |
---|---|
Barbara Ann Karmanos Cancer Institute | Detroit, Michigan 48201 |